APGE — Apogee Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1974640 ·
Last close
$133.65
Market Cap
$8.25B
52W High
$133.87
52W Low
$75.00
ADV30
4,420,729
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -82,772,000 | -74,111,000 | 1,293,654,000 | 451,797,000 | 37,861,000 |
| Dec 2025 | 0 | — | -78,056,000 | -69,387,000 | 937,134,000 | 131,549,000 | 33,251,000 |
| Sep 2025 | 0 | — | -71,278,000 | -65,021,000 | 626,159,000 | 107,914,000 | 39,821,000 |
| Jun 2025 | 0 | — | -73,165,000 | -66,096,000 | 657,772,000 | 124,192,000 | 38,371,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-234,543,000
Investing CF
$-227,905,000
Financing CF
$807,035,000
CapEx
$-5,898,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.18
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-635,870,000
Inventory
—
Receivables
$7,281,000
ST Investments
$608,088,000
EBIT TTM
$-305,271,000
Pretax Income TTM
$-274,341,000
Interest Exp TTM
—
Analysts
17
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -285,595,000 | -255,843,000 | 937,134,000 | 33,251,000 | — | -227,450,000 |
| Dec 2024 | 0 | -216,870,000 | -182,146,000 | 753,951,000 | 37,157,000 | — | -171,174,000 |
| Dec 2023 | 0 | -93,003,000 | -83,985,000 | 401,404,000 | 21,491,000 | — | -74,761,000 |
| Dec 2022 | 0 | -30,727,000 | -39,785,000 | 152,055,000 | 9,980,000 | — | -16,427,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.19
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMVT | Immunovant, Inc. | $8.15B | $39.71 | — |
| RGEN | REPLIGEN CORP | $8.14B | $144.24 | — |
| PCVX | Vaxcyte, Inc. | $8.41B | $58.21 | — |
| QGEN | QIAGEN N.V. | $8.56B | $41.51 | — |
| IBRX | ImmunityBio, Inc. | $8.61B | $8.22 | — |
News headlines (Yahoo Finance, 1h cache)
Apogee Therapeutics (APGE) Jumps Into Focus, Is The Stock Fully Valued?
2026-07-10 22:14 · Yahoo
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
2026-07-08 15:11 · Yahoo
What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?
2026-06-30 16:34 · Yahoo
AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last?
2026-06-29 14:19 · Yahoo
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why
2026-06-28 14:01 · Yahoo
AbbVie (ABBV) Wins Health Canada Approval for Boey
2026-06-28 00:07 · Yahoo
AbbVie (ABBV) to Acquire Apogee Therapeutics
2026-06-27 19:21 · Yahoo
2 Biotech Stocks Worth Buying Before Their Potential Buyouts
2026-06-27 18:05 · Yahoo
Is AbbVie a Buy After Its Purchase of Apogee?
2026-06-25 14:13 · Yahoo
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
2026-06-25 12:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.